Business Standard

Narayana Hrudayalaya Share Price

Know More

1277.508.35 (0.66%)

03:49 PM,16th Apr 2024

1276.951.85 (0.15%)

04:01 PM,16th Apr 2024

BSE : 539551


Sector : Health care

ISIN Code : INE410P01011

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Apr 16 2024 | 04:01 PM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)


Face Value


52-WK High


52-WK High Date

14 Feb 2024

52-WK Low


52-WK Low Date

18 Apr 2023

All Time High


All Time High Date

14 Feb 2024

All Time Low


All Time Low Date

30 Jan 2019

Narayana Hrudayalaya Ltd

Narayana Hrudayalaya Limited together with its subsidiaries and associates is primarily engaged in business of rendering medical and healthcare services. Narayana Hrudayalaya Limited the flagship company of the Group was incorporated on 19th July 2000 by Dr. Devi Prasad Shetty as its Founder. It has a network of 23 multi-speciality and super speciality hospitals with 7 heart centres spread across 18 locations in India and 1 multi-specialty hospital in Cayman Islands. During the financial year ended 31 March 2016 Company acquired the entire remaining 26% in Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) from Infrastructure Development Corporation (Karnataka) Limited (IDECK) by paying Rs 3025.60 Lacs as total purchase consideration to make NHSHPL as its wholly owned subsidiary. During the year under review the company through its wholly owned subsidiary entered into an agreement with prominent Kenyan doctors and couple of leading international financial institutions to establish a multi-specialty hospital in Nairobi Kenya. The company through its wholly owned subsidiary would initially own 26% equity stake in the operational entity for a consideration of USD 1.325 million. The multi-specialty hospital will be a state of the art tertiary care facility poised to cater to patients across different specialties. The 130 bedded hospital will provide affordable quality care that Narayana stands for to the patients from Kenya and neighbouring African countries. During the year under review the company received National Accreditation Board for Hospitals & Healthcare Providers (NABH) accreditation for 5 new units viz. HSR Guwahati Ahmedabad Jamshedpur and Mysore.Asia Healthcare Development Limited (AHDL) was a wholly owned subsidiary of the Company which was engaged in the business of operation of hospitals clinics health centers nursing homes and other related activities. The Company was sold in November 2016 to Lila Hospitals Private Limited by executing a Share Purchase Agreement for the sale of all its shares for a consideration of Rs. 38.34 lacs.The promoters and promoter group of the company other shareholders (JP Morgan Mauritius Holdings Ambadevi Mauritius Holdings Ashoka Investment Holdings) offloaded a total of 2.45 crore equity shares of Narayana Hrudayalaya by way of an initial public offer (IPO). The IPO was open for subscription during the period from 17 to 21 December 2015. There was no fresh issue of shares from the company. The company got its securities listed on BSE Limited and on National Stock Exchange of India Limited on 6 January 2016.During the year ended 31st March 2016 the Company completed the Initial Public Offering (IPO) through an offer for sale by existing shareholders to the extent of 24523297 equity shares of face value of Rs10 each for a cash price of Rs 250 per equity share including a premium of Rs 240 per equity share of 6287978 equity shares by Ashoka Investment Holdings Limited 1886455 equity shares by Ambadevi Mauritius Holdings Limited 12261648 equity shares by JP Morgan Mauritius Holdings IV Limited 2043608 equity shares by Dr. Devi Prasad Shetty and 2043608 equity shares by Shakuntala Shetty aggregating to Rs 6130.82 million and the equity shares of the Company were listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited on 6th January 2016.At the beginning of the financial year ended 31 March 2017 Narayana Hrydayalaya made significant investments by acquiring NewRise Healthcare Private Limited from Panacea Biotech Limited at an enterprise value of Rs 180 crore. On the organic route the company started fiscal 2016-17 with the commissioning of its super speciality facility at Kakriyal Jammu (established in partnership with Shri Mata Vaishno Devi Shrine Board). The 230 bedded facility is a state-of-the-art tertiary care facility catering to patients across 20 different specialities with a particular focus on cardiac sciences and oncologyPursuant to a Share Purchase Agreement executed in November 2016 Asia Healthcare Development Limited was sold to Lila Hospitals Private Limited. Narayana Hrydayalaya's subsidiary Narayana Hrudayalaya Hospitals Malaysia Sdn Bhd (Narayana Malaysia) filed an application for voluntary liquidation pursuant to Section 257(1) of the Companies Act 1965 of Malaysia in January 2017.During the financial year ended 31 March 2017 the company launched a dedicated 30 bedded platinum wing in Mazumdar Shaw Medical Centre Bengaluru to offer world-class services and comfort in line with international standards of dedicated care and hospitality. During the year under review the company partnered with Cisco to offer affordable remote diagnostic capabilities; this digital telemedicine solution would deliver advanced specialized healthcare services remotely in various parts of the country.Narayana Hrydayalaya's wholly owned subsidiary Narayana Hrudayalaya Surgical Hospital Private Limited (NHSHPL) entered into a Healthcare Services Agreement in March 2017 with Dharamshila Cancer Foundation and Research Centre for operating a hospital in New Delhi. NHSHPL is engaged in the business of operating and maintaining hospitals clinics health centers nursing homes and other related activities.Towards the beginning the financial year ended 31 March 2018 the company commissioned SRCC Children's Hospital at Haji Ali Park Mahalaxmi in Mumbai. The facility is operated and managed by Narayana Hrydayalaya and backed by SRCC an institution renowned for serving the needs of children from all sections of society. SRCC Children's Hospital is the company's maiden foray in Mumbai and a well-calibrated step in line with the group strategy to reinforce its presence across selected regional clusters. Narayana Hrydayalaya also acquired) a ~230 bedded near complete hospital at Gurugram in early 2017-18.During the financial year ended 31 March 2018 NewRise Healthcare Private Limited (NRHPL) was merged with the company vide Regional Director's Order dated 4 October 2017. NRHPL was a wholly owned subsidiary of the company which was acquired from Panacea Biotech Limited during the year under review. The company commissioned 2nd LINAC at Westbank in June 2017. The wholly owned subsidiary company Narayana Cayman Holdings Ltd. was merged with the step-down subsidiary Health City Cayman Islands Ltd. through Scheme of Merger effective April 1 2021.In 2023 The Health City Cayman Islands Ltd. (HCCI) acquired the 100% Ordinary Shares in the ENT in Cayman Ltd. on 3rd March 2023. Accordingly ENT in Cayman Ltd. was made a 100% step-down subsidiary of the Company. In 2022-23 the Company through a Business Transfer Agreement (BTA) with hiva and Shiva Orthopaedic Hospital Private Limited acquired its Orthopaedic and Trauma Hospital effective from October 1 2022 as a going concern on slump sale basis for an aggregate cash consideration of Rs 200 Crores. The Company launched its first ever Cadaveric Liver & Kidney Transplant at DNSH Delhi. Narayana Multispecialty Hospital Jaipur performed its First Liver Transplant in FY23. Narayana Multispecialty Hospital Jaipur commissioned its new LINAC Machine further bolstering its capabilities in the field of Oncology. Narayana Institute of CardiacSciences (NICS) in Health City Bengaluru operationalized three new Operating Rooms expanding its capacity to serve patients in need of surgical procedures. Mazumdar Shah Medical Centre (MSMC) Bengaluru acquired the Sparsh Hospital unit it its HealthCity premises in Bommasandra and expanded its scope of clinical services by launching the Dept. of Orthopaedics & Joint Replacement. MSMC went on to become the largest Bone Marrow Transplant (BMT) facility in India with a total capacity of 35 Bone Marrow Transplant (BMT) beds. Dharamshila Narayana Superspecialty Hospital (DNSH) in Delhi expanded its clinical servicesby adding Da Vinci Robot and launching Robotic GI Surgery providing patients with access to cutting-edge surgical technology.The Unit also upgraded its Radiation Therapy system to Versa HD platform installed an Advanced Nurse Call Bell System with PatientTracker & Announcement Facility and conducted its first successful Cadaveric Liver Transplant in the year.

Narayana Hrudayalaya Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 10
Latest Dividend (%)25.00
Latest Dividend Date 07 Jul 2023
Dividend Yield (%) 0.20
Book Value Share (₹) [S]78.51
P/B Ratio (₹) [S]16.27
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
AXIS Small Cap Fund (G) 713.74 5559600 3.75
AXIS Small Cap Fund (IDCW) 713.74 5559600 3.75
AXIS Small Cap Fund - Direct (G) 713.74 5559600 3.75
AXIS Small Cap Fund - Direct (IDCW) 713.74 5559600 3.75
DSP Small Cap Fund (G) 231.24 1801189 1.77
DSP Small Cap Fund (IDCW) 231.24 1801189 1.77
DSP Small Cap Fund - Direct (IDCW) 231.24 1801189 1.77
DSP Small Cap Fund - Direct (G) 231.24 1801189 1.77
Nippon India Pharma Fund (G) 192.73 1501224 2.70
Nippon India Pharma Fund (Bonus) 192.73 1501224 2.70

Load more

Research Reports

Date BrokerActionPrices(Rs)Report
24-05-2023Prabhudas Lilladher Buy 827
13-02-2023Prabhudas Lilladher Buy 719

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week-2.82%-3.05%-2.33-2.19%
1 Month2.82%2.83%0.410.57%
3 Month1.28%1.36%-0.250.52%
6 Month17.49%17.48%10.2412.24%
1 Year64.73%64.89%20.7124.23%
3 Year218.18%218.18%49.3851.51%

Company Info

Company Information

Chairman & Exec. Director : DEVI PRASAD SHETTY

Managing Director & CEO : Ashutosh Raghuvanshi

Whole-time Director : Viren Shetty

Director : Kiran Mazumdar Shaw

Independent Director : Dinesh Krishna Swamy

Independent Director : B Muthuraman

Independent Director : B N Subramanya

Independent Director : Manohar D Chatlani

Company Secretary : Sridhar S

Independent Director : Arun Seth

Registered Office: No 258/A Bommasandra Indl Area, Anekal Taluq,Bengaluru,Karnataka-560099 Ph: 91-80-71222802